Supernus Pharmaceuticals Announces Q4 2025 Earnings

The specialty pharmaceutical company is set to report financial results on Tuesday, February 24th.

Feb. 22, 2026 at 6:52am

Got story updates? Submit your updates here. ›

Supernus Pharmaceuticals (NASDAQ:SUPN), a specialty pharmaceutical company focused on central nervous system therapies, is expected to announce its Q4 2025 financial results before the market opens on Tuesday, February 24th. Analysts forecast the company will report earnings of $0.41 per share for the quarter.

Why it matters

As a publicly traded pharmaceutical company, Supernus’ quarterly earnings reports are closely watched by investors to gauge the performance and growth potential of its portfolio of central nervous system medications, including its flagship products Trokendi XR, Oxtellar XR, and the recently approved ADHD treatment Qelbree.

The details

Supernus Pharmaceuticals, headquartered in Rockville, Maryland, has built a specialty pharmaceutical business around developing and commercializing extended-release formulations of drugs to treat neurological disorders. The company’s Q4 2025 earnings announcement will provide the latest update on the commercial performance of its product portfolio and any pipeline developments.

  • Supernus Pharmaceuticals is expected to announce its Q4 2025 earnings before the market opens on Tuesday, February 24, 2026.
  • The company’s Q4 2025 earnings call is scheduled for Tuesday, February 24, 2026 at 4:30 PM ET.

The players

Supernus Pharmaceuticals

A specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies, including extended-release formulations of drugs to treat neurological disorders.

Padmanabh P. Bhatt

Vice President at Supernus Pharmaceuticals who sold 710 shares of the company’s stock in December 2025.

Frank Mottola

Senior Vice President at Supernus Pharmaceuticals who sold 20,000 shares of the company’s stock in December 2025.

Got photos? Submit your photos here. ›

What’s next

Supernus Pharmaceuticals is expected to hold its Q4 2025 earnings call on Tuesday, February 24, 2026 at 4:30 PM ET.

The takeaway

As a specialty pharmaceutical company focused on central nervous system therapies, Supernus’ upcoming earnings report will provide investors with the latest updates on the commercial performance of its key products and any pipeline developments that could drive future growth.